Shares of Biocon today tumbled 6 per cent after the biotechnology major said the US health regulator had made seven observations after inspection of its sterile drug product manufacturing facility in Bengaluru.
The stock plunged 5.81 per cent to Rs 624.90 on BSE.
On NSE, shares of the company dropped 5.97 per cent to Rs 624.30.
The observations are largely procedural and aimed at continuous improvement, Biocon said in a filing to BSE yesterday.
The USFDA has completed pre-approval inspection of the sterile drug product manufacturing facility in Bengaluru this week and issued a Form 483 with 7 observations, the filing said.
"We will respond to the USFDA with a corrective and preventive action plan in a timely manner," a Biocon spokesperson said.
An FDA Form 483 is issued to firm management at the conclusion of an inspection by the USFDA. It notifies the company's management of objectionable conditions at the facility.
Disclaimer: No Business Standard Journalist was involved in creation of this content
